Payment overview · 2025
General Payments
$144.31
7 reported records · 5 companies
Healthcare provider profile · identity verified
Matthew G Mischel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VAN NUYS, CA · NPI 1013996172
Verified facts
What the public records show
CMS Open Payments records show Matthew G Mischel, M.D. received $144.31 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.29 | 28.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 26.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.63 | 19.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.53 | 13.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.16 | 11.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.61 | 5 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 179 | 37 |
| Alprazolam | Alprazolam | 177 | 49 |
| Losartan Potassium | Losartan Potassium | 176 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 56 |
| Metformin Hcl | Metformin Hcl | 169 | 49 |
| Lisinopril | Lisinopril | 160 | 43 |
| Simvastatin | Simvastatin | 144 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 30 |
| Trazodone Hcl | Trazodone Hcl | 111 | 37 |
| Gabapentin | Gabapentin | 101 | 37 |
| Eliquis | Apixaban | 98 | 25 |
| Furosemide | Furosemide | 86 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 28 |
| Allopurinol | Allopurinol | 79 | 21 |
| Azithromycin | Azithromycin | 76 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 23 |
| Tramadol Hcl | Tramadol Hcl | 74 | 17 |
| Omeprazole | Omeprazole | 71 | 20 |
| Lorazepam | Lorazepam | 68 | 20 |
| Temazepam | Temazepam | 66 | 15 |
| Valsartan | Valsartan | 66 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 16 |
| Ezetimibe | Ezetimibe | 60 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 58 | 16 |
| Ozempic | Semaglutide | 57 | 12 |
| Alendronate Sodium | Alendronate Sodium | 55 | 18 |
| Januvia | Sitagliptin Phosphate | 53 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 14 |
| Potassium Chloride | Potassium Chloride | 53 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 12 |
| Jardiance | Empagliflozin | 52 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Nifedipine Er | Nifedipine | 50 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 14 |
| Famotidine | Famotidine | 46 | 13 |
| Meloxicam | Meloxicam | 45 | 18 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 32 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 43 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Diazepam | Diazepam | 41 | 13 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Carvedilol | Carvedilol | 39 | 15 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 13 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Prednisone | Prednisone | 34 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 11 |
| Calcitriol | Calcitriol | 30 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $144.31 · 7 records | ABBVIE INC. | Cologuard Collection Kit, EVENITY, JARDIANCE, QULIPTA, TRELEGY ELLIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error